Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. 1986

H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki

We performed a hemostatic evaluation in detail in a patient with suspected amyloidosis who was suffering from several bleeding episodes. He had a shortened euglobulin clot lysis time, decreased alpha 2-plasmin inhibitor (alpha 2-PI), decreased plasminogen, elevated tissue-type plasminogen activator (t-PA), elevated plasmin-alpha 2-PI complex, and decreased ratio of ristocetin cofactor to von Willebrand factor (vWF) antigen. Fibrinogen and fibrin/fibrinogen degradation products levels fluctuated, with abnormal values on several occasions. On crossed immunoelectrophoresis, plasmin-alpha 2-PI complex and vWF fragment were demonstrated in the patient plasma. These abnormal findings and bleeding symptoms improved following the administration of tranexamic acid. Discontinuation of tranexamic acid resulted in deterioration of these parameters. These observations indicate that pathologic fibrinolysis (continuous intravascular plasmin generation) characterized by the consumption of alpha 2-PI and plasminogen, formation of plasmin-alpha 2-PI complex, and fragmentation of vWF contributed to the bleeding in this patient. It is important to recognize excessive fibrinolysis as the underlying cause of bleeding in these patients, since specific treatment with antifibrinolytic agents is effective in controlling the bleeding.

UI MeSH Term Description Entries
D007123 Immunoelectrophoresis, Two-Dimensional Immunoelectrophoresis in which a second electrophoretic transport is performed on the initially separated antigen fragments into an antibody-containing medium in a direction perpendicular to the first electrophoresis. Immunoelectrophoresis, Crossed,Immunoelectrophoresis, 2-D,Immunoelectrophoresis, 2D,2-D Immunoelectrophoresis,2D Immunoelectrophoresis,Crossed Immunoelectrophoresis,Immunoelectrophoresis, 2 D,Immunoelectrophoresis, Two Dimensional,Two-Dimensional Immunoelectrophoresis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006406 Hematoma A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue. Hematomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses

Related Publications

H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
September 1985, The American journal of medicine,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
January 1989, Journal of neurosurgery,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
November 2001, Neurosurgery,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
January 1990, The Journal of diabetic complications,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
July 1991, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
September 1989, Thrombosis research,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
July 1988, American journal of hematology,
H Takahashi, and T Koike, and N Yoshida, and O Kitahara, and M Hanano, and A Shibata, and N Aoki
March 1986, Thrombosis research,
Copied contents to your clipboard!